SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, the Company's Chairman & CEO, will preside over the opening bell on Friday, May 13, 2005 at 9:30 a.m. Eastern Time.
Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "We are extremely pleased to celebrate the one year anniversary of our IPO on NASDAQ with our participation in this opening bell ceremony. Our listing this time last year marked a significant milestone for NuVasive. Within the past year, we've built substantial momentum in the adoption of our Maximum Access Surgery product platform among spine surgeons, produced robust financial results and relocated to a new, state-of-the-art facility greatly expanding our training, distribution and customer service capabilities. We also expect to release 9 new products this year to further expand our market reach and penetration. I am very grateful to our customers, shareowners and investors for their tremendous support and for the honor of representing NuVasive on this momentous occasion."
A live web cam view of the opening bell ceremony, provided by NASDAQ, will be accessible via the NuVasive website http://www.nuvasive.com.
We are a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. Our product portfolio is focused on applications in the over $2 billion U.S. spine fusion market. Our current principal product offering includes a minimally disruptive surgical platform that we call Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.
The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of our current product offerings-NeuroVision(R), a proprietary software-driven nerve avoidance system, MaXcess(R), a unique split-blade design retraction system and specialized implants, like SpheRx(TM) and CoRoent(TM)-that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. Our classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and metal mesh cages. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products such as Total Disc Replacement (TDR).
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, the rapidly changing and competitive nature of the medical device industry, NuVasive's ability to convince surgeons to use its products, the ability of patients to obtain third-party reimbursement for surgical procedures employing NuVasive's products, risks related to government regulation of medical devices, risks related to NuVasive's ability to effectively manage the growth of its business, risks related to ownership and enforcement of intellectual property rights, NuVasive's ability to successfully develop new products, and other risks and uncertainties more fully described in NuVasive's Annual Report on Form 10-K filed with the Securities and Exchange Commission and NuVasive's Prospectus filed pursuant to Rule 424 under the Securities Act of 1933. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Contact: Investors: Kevin C. O'Boyle Stephanie Carrington/Nick Laudico EVP & Chief Financial Officer The Ruth Group NuVasive, Inc. 646-536-7017/7030 858-909-1800 email@example.com firstname.lastname@example.org email@example.com
Kevin C. O'Boyle,
EVP & Chief Financial Officer of NuVasive, Inc.,
both of The Ruth Group, for NuVasive, Inc.
Web site: http://www.nuvasive.com